
Claims

1. An oral dosage form in the form of a capsule which comprises: 1) Compound A of the following structure:



,

or a pharmaceutically acceptable salt, hydrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount of about 0.1 to about 3 weight percent of the total weight of the dosage form; 2) a carrier or excipient at an amount of about 90 to 99.9 weight percent of total weight of the oral dosage form, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid.

2. The oral dosage form of claim 1, wherein Compound A is present at an amount of about 0.1 to about 1 weight percent of total weight of the dosage form.

3. The oral dosage form of claim 1, wherein the carrier or excipient is present at an amount of about 95 to about 99.9 weight percent of total weight of the dosage form.

4. The oral dosage form of claim 1, wherein the weight ratio of lactose to starch in the oral dosage form is from about 1:1 to about 5:1.

5. The oral dosage form of claim 4, wherein the weight ratio of lactose to starch in the oral dosage form is about 3:1.


6. The oral dosage form of claim 1, wherein the starch is pregelatinized starch.

7. The oral dosage form of claim 1, wherein the lactose is anhydrous lactose.

8. The oral dosage form of claim 1, wherein the lubricant is present at an amount of 0.01 to 1 weight percent of total weight of the dosage form.

9. The oral dosage form of claim 8, wherein the lubricant is present at an amount of 0.1 to 0.5 weight percent of total weight of the dosage form.

10. The oral dosage form of claim 1, which weighs about 75 mg and comprises: 1) Compound A of the following structure:



,

or a pharmaceutically acceptable salt, hydrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.3 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid.

11. The oral dosage form of claim 10, wherein the starch is pregelatinized starch.

12. The oral dosage form of claim 11, wherein the pregelatinized starch is present at an amount of about 18.075 mg.


13. The oral dosage form of claim 10, wherein the stearic acid is present at an amount of about 0.225 mg.

14. The oral dosage form of claim 10, wherein the lactose is anhydrous lactose.

15. The oral dosage form of claim 14, wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 75 mg.

16. The oral dosage form of claim 10, which is in the form of a size 4 or larger capsule.

17. The oral dosage form of claim 1, which weighs about 75 mg and comprises: 1) Compound A of the following structure:



,

or a pharmaceutically acceptable salt, hydrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.1 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid.

18. The oral dosage form of claim 17, wherein the starch is pregelatinized starch.

19. The oral dosage form of claim 18, wherein the pregelatinized starch is present at an amount of about 18.75 mg.


20. The oral dosage form of claim 17, wherein the stearic acid is present at an amount of about 0.225 mg.

21. The oral dosage form of claim 17, wherein the lactose is anhydrous lactose.

22. The oral dosage form of claim 21, wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 75 mg.

23. The oral dosage form of claim 17, which is in the form of a size 4 or larger capsule.

24. The oral dosage form of claim 1, which weighs about 150 mg and comprises: 1) Compound A of the following structure:



,

or a pharmaceutically acceptable salt, hydrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.2 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid.

25. The oral dosage form of claim 24, wherein the starch is pregelatinized starch.

26. The oral dosage form of claim 25, wherein the pregelatinized starch is present at an amount of about 37.5 mg.


27. The oral dosage form of claim 24, wherein the stearic acid is present at an amount of about 0.45 mg.

28. The oral dosage form of claim 24, wherein the lactose is anhydrous lactose.

29. The oral dosage form of claim 28, wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 150 mg.

30. The oral dosage form of claim 24, which is in the form of a size 3 or larger capsule.

31. The oral dosage form of claim 1, which weighs about 125 mg and comprises: 1) Compound A of the following structure:



,

or a pharmaceutically acceptable salt, hydrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.5 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid.

32. The oral dosage form of claim 31, wherein the starch is pregelatinized starch.

33. The oral dosage form of claim 32, wherein the pregelatinized starch is present at an amount of about 31.25 mg.

34. The oral dosage form of claim 31, wherein the stearic acid is present at an amount of about 0.375 mg.

35. The oral dosage form of claim 31, wherein the lactose is anhydrous lactose.

36. The oral dosage form of claim 35, wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 125 mg.

37. The oral dosage form of claim 31, which is in the form of a size 3 or larger capsule.

38. An oral dosage form of any one of claims 1 to 37, for use in a method for treating, preventing, or managing a disease or disorder, wherein the oral dosage form is to be administered to a patient, wherein the disease or disorder is cancer, lupus, scleroderma, lupus pernio, sarcoidosis, Sjögren syndrome, ANCA-induced vasculitis, anti-phospholipid syndrome, myasthenia gravis, Addison’s disease, alopecia areata, ankylosing spondylitis, antiphospholipid

antibody syndrome, antiphospholipid syndrome, primary or secondary antiphospholipid syndrome, asthma, autoimmune gastritis, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative disease, autoimmune thrombocytopenic purpura, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy, cicatrical pemphigoid, particularly mucous membrane pemphigoid, cold agglutinin disease, degos disease, dermatitis hepatiformis, essential mixed cryoglobulinemia, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis (Hashimoto's disease; autoimmune thyroditis), idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura, IgA nephropathy, juvenile arthritis, lichen planus, Ménière disease, mixed connective tissue disease, morephea, narcolepsy, neuromyotonia, pediatric autoimmune neuropsychiatric disorders (PANDAs), pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polymyalgia rheumatica, primary agammaglobulinemia, primary biliary cirrhosis, Raynaud disease (Raynaud phenomenon), Reiter's syndrome, relapsing polychondritis, rheumatic fever, Sjogren's syndrome, stiff-person syndrome (Moersch-Woltmann syndrome), Takayasu's arteritis, temporal arteritis (giant cell arteritis), uveitis, vasculitis, particularly vasculitis not associated with lupus erythematosus, vitiligo, or Wegener's granulomatosis.

39. The oral dosage form of any one of claims 1 to 37 for use of claim 38, wherein the disease or disorder is cancer, and wherein the cancer is advanced malignancy, amyloidosis, neuroblastoma, meningioma, hemangiopericytoma, multiple brain metastases, glioblastoma multiforms, glioblastoma, brain stem glioma, poor prognosis malignant brain tumor, malignant glioma, anaplastic astrocytoma, anaplastic oligodendroglioma, neuroendocrine tumor, rectal adenocarcinoma, Dukes C & D colorectal cancer, unresectable colorectal carcinoma, metastatic hepatocellular carcinoma, Kaposi's sarcoma, karotype acute myeloblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cutaneous T-Cell lymphoma, cutaneous B-Cell lymphoma, diffuse large B-Cell lymphoma, low grade follicular lymphoma, malignant melanoma, malignant mesothelioma, malignant pleural effusion mesothelioma syndrome, peritoneal carcinoma, papillary serous carcinoma, gynecologic sarcoma, soft tissue sarcoma, scleroderma, cutaneous vasculitis, Langerhans cell histiocytosis, leiomyosarcoma, fibrodysplasia

ossificans progressive, hormone refractory prostate cancer, resected high-risk soft tissue sarcoma, unrescectable hepatocellular carcinoma, Waldenstrom's macroglobulinemia, smoldering myeloma, indolent myeloma, fallopian tube cancer, androgen independent prostate cancer, androgen dependent stage IV non-metastatic prostate cancer, hormone-insensitive prostate cancer, chemotherapy-insensitive prostate cancer, papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, or leiomyoma.

40. The oral dosage form of any one of claims 1 to 37 for use of claim 38, wherein the disease or disorder is cancer, and wherein the cancer is a blood borne tumor.

41. The oral dosage form of any one of claims 1 to 37 for use of claim 38, wherein the disease or disorder is cancer, and wherein the cancer is myeloma, leukemia or lymphoma.

42. The oral dosage form of any one of claims 1 to 37 for use of claim 38, wherein the disease or disorder is cancer, and wherein the cancer is a solid tumor.

43. The oral dosage form of any one of claims 1 to 37 for use of claim 38, wherein the disease or disorder is cancer, and wherein the cancer is breast, colorectal, ovarian, prostate, pancreatic, or renal cancer.

44. The oral dosage form of any one of claims 1 to 37 for use of claim 38, wherein the disease or disorder is cancer, and wherein the cancer is hepatocellular carcinoma, prostate cancer, ovarian cancer, or glioblastoma.

45. The oral dosage form of any one of claims 1 to 37 for use of claim 38, wherein the disease or disorder is cancer, and wherein the cancer is non-Hodgkin's lymphoma.

46. The oral dosage form of any one of claims 1 to 37 for use of claim 45, wherein the non-Hodgkin's lymphoma is diffuse large B-cell lymphoma.

47. The oral dosage form of any one of claims 1 to 37 for use of claim 46, wherein the diffuse large B-cell lymphoma is of the activated B-cell phenotype.

48. The oral dosage form of any one of claims 1 to 37 for use of claim 47, wherein the diffuse large B-cell lymphoma is characterized by the expression of one or more biomarkers overexpressed in RIVA, U2932, TMD8 or OCI-Ly10 cell lines.

49. The oral dosage form of any one of claims 1 to 37 for use of claim 38, wherein the disease or disorder is cancer, and wherein the cancer is multiple myeloma.

50. The oral dosage form of any one of claims 1 to 37 for use of any one of claims 38 to 49, wherein the cancer is relapsed or refractory.

51. The oral dosage form of any one of claims 1 to 37 for use of any one of claims 38 to 50, wherein the cancer is drug-resistant.